ABL1 and acute lymphoblastic leukemia: Thus, our data suggest that LCK and SRC are highly active in T-ALL, but the pharmacological inhibition of these activities is only effective in HSB-2 and ALL-SIL that harbor rearrangements in LCK or NUP214-ABL1, respectively.